Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC

Kloskowski,Tomasz; Gurtowska,Natalia; Olkowska,Joanna; Nowak,Jakub  Marcin; Adamowicz,Jan; Tworkiewicz,Jakub; Dębski,Robert; Grzanka,Alina; Drewa,Tomasz

doi:10.3892/ijo.2012.1653

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC

Authors:
- Tomasz Kloskowski
- Natalia Gurtowska
- Joanna Olkowska
- Jakub Marcin Nowak
- Jan Adamowicz
- Jakub Tworkiewicz
- Robert Dębski
- Alina Grzanka
- Tomasz Drewa
View Affiliations

Affiliations: Department of Tissue Engineering, Nicolaus Copernicus University, Bydgoszcz, Poland, Department of Histology and Embryology, Nicolaus Copernicus University, Bydgoszcz, Poland, Laboratory of Clinical and Experimental Oncology, Department of Pediatric, Hematology and Oncology Nicolaus Copernicus University, Bydgoszcz, Poland
Published online on: October 4, 2012 https://doi.org/10.3892/ijo.2012.1653
Pages: 1943-1949
Copyright: © Kloskowski et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common tumors and its treatment is still inefficient. In our previous work we proved that ciprofloxacin has a different influence on five cancer cell lines. Here, we aimed to compare the biological effect of ciprofloxacin on cell lines representing different responses after treatment, thus A549 was chosen as a sensitive model, C6 and B16 as highly resistant. Three different cell lines were analyzed (A549, B16 and C6). The characterization of continuous cell growth was analyzed with the Real-Time Cell Analyzer (RTCA)-DP system. Cytoskeletal changes were demonstrated using immunofluorescence. The cell cycle was analyzed using flow cytometry. Ciprofloxacin was cytostatic only against the A549 cell line. In the case of other tested cell lines a cytostatic effect was not observed. Cytoskeletal analysis confirms the results obtained with RTCA-DP. A549 cells were inhibited in the G2/M phase suggesting a mechanism related to topoisomerase II inhibition. The biological effects of ciprofloxacin support the hypothesis that this drug can serve as an adjuvant treatment for lung cancer, due to its properties enabling topoisomerase II inhibition.

View Figures

View References

1.	SS HechtTobacco smoke carcinogens and lung cancerJ Natl Cancer Inst9111941210199910.1093/jnci/91.14.119410413421
2.	R RosellA VergnenegreB LiuBiomarkers in lung oncologyPulm Pharmacol Ther23508514201010.1016/j.pupt.2010.05.00320471486
3.	JT LouieCiprofloxacin: an oral quinolone for the treatment of infections with gram-negatine pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease SocietyCMAJ15066967619948313286
4.	N SipsasC KosmasP ZiakasComparison of two oral regiments for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: Ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanateScand J Infect Dis39786791200710.1080/00365540701367769
5.	S HaraguchiM HiokiK YamashitaCiprofloxacin penetration into the pulmonary parenchyma in Japanese patientsSurg Today37282284200710.1007/s00595-006-3393-417387558
6.	A DalhoffImmunomodulatory activities of fluoroquinolonesInfection33S55S70200510.1007/s15010-005-8209-8
7.	K DrlicaMechanism of fluoroquinolone actionCurr Opin Microbiol2504508199910.1016/S1369-5274(99)00008-910508721
8.	T KloskowskiN GurtowskaM NowakR JoachimiakA BajekJ OlkowskaT DrewaThe influence of ciprofloxacin on A549, HepG2, A375.S2, B16 and C6 cell lines in vitroActa Pol Pharm68859865201110.5506/APhysPolB.42.85922125950
9.	T KloskowskiN GurtowskaT DrewaDoes ciprofloxacin have an obverse and a reverse?Pulm Pharmacol Ther23373375201010.1016/j.pupt.2010.02.00520211752
10.	N GurtowskaT KloskowskiT DrewaCiprofloxacin criteria in antimicrobial prophylaxis and bladder cancer recurrenceMed Sci Monit16218223201020885364
11.	T KloskowskiJ OlkowskaA NazlicaT DrewaThe influence of ciprofloxacin on hamster ovarian cancer cell line CHO AA8Acta Pol Pharm67345349201020635529
12.	N KeX WangX XuYA AbassiThe xCELLigence system for real-time and label-free monitoring of cell viabilityMethods Mol Biol7403343201110.1007/978-1-61779-108-6_621468966
13.	RE GonzalezCU LimK ColeCH BianchiniGP SchoolsBE DavisI WadaIB RoninsonEV BroudeEffects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cellsCell Cycle1035053514201110.4161/cc.10.20.1777822067657
14.	P BenesL KnopfovaF TrckaInhibition of topoisomerase IIα: Novel function of wedelolactoneCancer Lett30329382011
15.	R SrivastavaApoptosis, Cell Signaling, and Human DiseasesHumana PressTotowa, NJ2007
16.	EJ CalabreseLA BaldwinHormesis: U-shaped dose responses and their centrality in toxicologyTrends in Pharmacol Sci22285291200110.1016/S0165-6147(00)01719-311395156
17.	A GürbayF HincaA FavierCytotoxic effect of ciprofloxacin in primary culture of rat astrocytes and protection by vitamin EToxicology2295461200717098346
18.	O AranhaDP WoodFU SarkarCiprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in human transitional cell carcinoma of the bladder cell lineClin Cancer Res6891900200010741713
19.	ER MondalSK DasP MukherjeeComparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in cultureAsian Pac J Cancer Prev5196204200415244525
20.	R RohwedderT BerganE CarusoSB ThorsteinssonH Della TorreH SchollPenetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacinChemotherapy37229238199110.1159/0002388601790720
21.	IS KourbetiDE AlegakisS MarakiG SamonisImpact of prolonged treatment with high-dose ciprofloxacin on human gut flora: a case reportJ Med Case Rep4111201010.1186/1752-1947-4-11120409330
22.	TR UtrupEW MuellerDP HealyRA CallcutJD PetersonWE HurfordHigh-dose ciprofloxacin for serious gram-negative infection in an obese, critically III patient receiving continuous venovenous hemodiafiltrationAnn Pharmacother4416601664201010.1345/aph.1P234
23.	S ChonoT TaninoT SekiK MorimotoPharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infectionsDrug Metab Pharmacokinet228895200710.2133/dmpk.22.8817495415